Ante S Lundberg from 157 Day St, Newton, MA 02466, Phone: 617 795-2179

Ante S. Lundberg

Address:

3806 Williams Ln, Chevy Chase, MD 20815

License #:

MD5801 - Expired

Category:

MEDICINE

Issued Date:

Apr 14, 1972

Expiration Date:

Dec 31, 2010

Type:

MEDICINE AND SURGERY

Dr. Ante S Lundberg, Boston MA - MD (Doctor of Medicine)

view source

Specialties:

Internal Medicine

Address:

150 S Huntington Ave, Boston, MA 02130
617 232-9500 (Phone), 617 232-9500 (Fax)

Certifications:

Internal Medicine, 1994

Awards:

Healthgrades Honor Roll

Languages:

English

Education:

Medical School
Stanford University
Graduated: 1990
Medical School
Brigham and Womens Hospital
Graduated: 1990
Medical School
Dana-Farber Cancer Institute
Graduated: 1990

Ante Sven Lundberg

view source

Specialties:

Internal Medicine
Medical Oncology

Education:

Stanford University (1990)

Ante Sven Lundberg, Jamaica Plain MA

view source

Specialties:

Oncologist

Address:

150 S Huntington Ave, Jamaica Plain, MA 02130

Education:

Stanford University, School of Medicine - Doctor of Medicine
Dana-Farber Cancer Institute - Fellowship - Oncology (Internal Medicine)

Isbn (Books And Publications)

The Environment And Mental Health: A Guide For Clinicians
view source
Author:

Ante Lundberg
ISBN #:

0805829075

Us Patents

Use Of An Epidermal Growth Factor Receptor Kinase Inhibitor (Egfr) In Gefitinib Resistant Patients
view source
US Patent:

20060235046, Oct 19, 2006
Filed:

Apr 12, 2006
Appl. No.:

11/403170
Inventors:

Charles Zacharchuk - Westford MA, US
Susan Quinn - Norwood MA, US
Patricia Martins - Somerville MA, US
Lee Greenberger - Montclair NJ, US
Ante Lundberg - Newton MA, US
Assignee:

Wyeth - Madison NJ
International Classification:

A61K 31/47
US Classification:

514313000
Abstract:

This invention discloses method of treating or inhibiting cancer in a human having at least one of an Exon 19 del E746-A750 and/or an Exon 21 point mutation comprising administering to said human gefitinib and/or iressa alone or in combination with other cytotoxic agents or chemotherapeutic agents and an effective amount of EGFR kinase inhibitor.

Materials And Methods For Treatment Of Hemoglobinopathies
view source
US Patent:

20220211874, Jul 7, 2022
Filed:

Feb 2, 2022
Appl. No.:

17/591563
Inventors:

- Boston MA, US
Ante Sven Lundberg - Cambridge MA, US
Tirtha Chakraborty - Cambridge MA, US
Michelle I-Ching Lin - Cambridge MA, US
Bibhu Prasad Mishra - Wakefield MA, US
Elizabeth Paik - Cambridge MA, US
Andrew Kernytsky - Cambridge MA, US
Todd Douglass Borland - Cambridge MA, US
Assignee:

Vertex Pharmaceuticals Incorporated - Boston MA
International Classification:

A61K 48/00
C12N 15/10
A61K 38/46
C12N 9/22
C12N 15/113
A61P 7/00
A61K 31/395
Abstract:

Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting, modulating, or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.

Materials And Methods For Treatment Of Amyotrophic Lateral Sclerosis And/Or Frontal Temporal Lobular Degeneration
view source
US Patent:

20210260219, Aug 26, 2021
Filed:

Dec 22, 2016
Appl. No.:

16/065535
Inventors:

- ZUG, CH
Ami Meda Kabadi - Cambridge MA, US
Ante Sven Lundberg - Cambridge MA, US
International Classification:

A61K 48/00
A61K 35/28
A61K 35/30
A61K 38/19
A61K 31/395
A61K 38/46
A61K 31/7105
A61K 35/761
A61K 41/00
A61P 25/28
C12N 15/90
C12N 5/0789
C12N 5/0797
C12N 5/0793
C12N 5/074
C12N 5/0775
Abstract:

The present application provides materials and methods for treating a patient with Amyotrophic Lateral Sclerosis (ALS) and/or Frontaltemporal Lobular Degeneration (FTLD), both ex vivo and in vivo. In addition, the present application provides materials and methods for editing to modulate the expression, function or activity of the C9ORF72 gene in a cell by genome editing.

Crispr-Cas9 Modified Cd34+ Human Hematopoietic Stem And Progenitor Cells And Uses Thereof
view source
US Patent:

20200384033, Dec 10, 2020
Filed:

Dec 5, 2018
Appl. No.:

16/769926
Inventors:

- Boston MA, US
Tirtha Chakraborty - Cambridge MA, US
Ante Sven Lundberg - Cambridge MA, US
Tony Ho - Cambridge MA, US
Laura Sandler - Cambridge MA, US
Brenda Eustace - Boston MA, US
Jerome Rossert - Boston MA, US
Robert Kauffman - Boston MA, US
Assignee:

Vertex Pharmaceuticals Incorporated - Boston MA
International Classification:

A61K 35/28
C12N 5/0789
C12N 15/11
C12N 9/22
C07K 14/805
A61K 31/395
A61K 38/19
A61K 35/18
A61K 31/255
A61P 7/00
Abstract:

Provided herein, in some embodiments, are methods and compositions for treatment of subjects with β-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.

Materials And Methods For Treatment Of Hemoglobinopathies
view source
US Patent:

20200330609, Oct 22, 2020
Filed:

Apr 18, 2017
Appl. No.:

16/094408
Inventors:

- Zug, CH
Ante Sven Lundberg - Cambridge MA, US
Tirtha Chakraborty - Cambridge MA, US
Michelle l-ching Lin - Cambridge MA, US
Bibhu Prasad Mishra - Cambridge MA, US
Elizabeth Jae-eun Paik - Cambridge MA, US
Andrew Kernytsky - Cambridge MA, US
Todd Douglass Borland - Cambridge MA, US
Assignee:

CRISPR Therapeutics AG - Zug
International Classification:

A61K 48/00
C12N 9/22
C12N 15/10
Abstract:

Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting, modulating, or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.

Materials And Methods For Treatment Of Glycogen Storage Disease Type 1A
view source
US Patent:

20190382798, Dec 19, 2019
Filed:

Nov 7, 2016
Appl. No.:

15/759202
Inventors:

- Basel, CH
Roman Lvovitch BOGORAD - Cambridge MA, US
Ante Sven LUNDBERG - Cambridge MA, US
Kirsten Leah BEAUDRY - Cambridge MA, US
International Classification:

C12N 15/90
C12N 9/22
C12N 9/16
C12N 15/11
Abstract:

The present application provides materials and methods for treating a patient with Glycogen Storage Disease type la (GSD1a) both ex vivo and in vivo. In addition, the present application provides materials and methods for modulating the expression, function, and/or activity of the glucose-6-phosphatase, catalytic (G6PC) and/or the glucose-6-phosphatase (G6Pase) protein in a cell by genome editing.

Materials And Methods For Treatment Of Duchenne Muscular Dystrophy
view source
US Patent:

20190374655, Dec 12, 2019
Filed:

Oct 28, 2016
Appl. No.:

15/763328
Inventors:

- Zug, CH
Chad Albert COWAN - Cambridge MA, US
Ante Sven LUNDBERG - Cambridge MA, US
International Classification:

A61K 48/00
C12N 9/22
A61K 38/46
C12N 15/113
C12N 15/90
A61P 21/00
A61P 25/14
Abstract:

The present application provides materials and methods for treating a patient with Duchenne Muscular Dystrophy (DMD) both ex vivo and in vivo. In addition, the present application provides materials and methods for editing a dystrophin gene in a cell by genome editing.

Materials And Methods For Treatment Of Hemoglobinopathies
view source
US Patent:

20190201553, Jul 4, 2019
Filed:

Mar 18, 2019
Appl. No.:

16/356373
Inventors:

- Zug, CH
Ante Sven Lundberg - Cambridge MA, US
Tirtha Chakraborty - Cambridge MA, US
Michelle I-ching Lin - Cambridge MA, US
Bibhu Prasad Mishra - Cambridge MA, US
Elizabeth Jae-eun Paik - Cambridge MA, US
Andrew Kernytsky - Cambridge MA, US
Todd Douglas Borland - Cambridge MA, US
Assignee:

CRISPR Therapeutics AG - Zug
International Classification:

A61K 48/00
A61K 31/395
A61P 7/00
Abstract:

Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting, modulating, or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.